Stocks · News reference

MIRA Pharma Announces Results Preclinical Studies Evaluating Optimized Oral Formulations Of MIRA-55, Oral Drug Candidate Being Developed As Non-Opioid Therapy For Chronic Inflammatory Pain

Jul 10, 2026, 12:03 PMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 10, 2026, 12:03 PM
Checked: Jul 10, 2026, 12:10 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 6, 2026, 12:15 PMBenzinga Newsdesk
MIRA Pharmaceuticals Says 7-Day Repeated-Dose Dog Study Of Obesity Candidate SKNY-1 Showed Dose-Dependent Exposure, Supporting Advancement Toward GLP Toxicology, IND-Enabling Work
Read original at benzinga
MIRA
SEC EDGARAug 6, 2026, 12:00 PMSEC EDGAR
8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)
Filed: 2026-08-06 AccNo: 0001493152-26-036262 Size: 234 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar
MIRA
BenzingaJul 30, 2026, 12:08 PMBenzinga Newsdesk
MIRA Pharmaceuticals Says It Completed Dosing In Exploratory Non-GLP 7-Day Toxicology Studies Of MIRA-55 And SKNY-1, Advancing Both Toward IND-Enabling Development
Read original at benzinga
MIRA